Lundbeck Highlights Vyepti Potential, But Company's 2021 Outlook Cautious

Lundbeck is focused on the global launch of its new migraine therapy Vyepti in the coming years, and the development of additional indications, as its reported a 4% increase in revenues in 2020 which were within its pre-pandemic guidance.